Body Mass Index | Underweight | Normal | Overweight | Obese I | Obese II |
BMI (kg/m2) | <18.5 | 18.5-22.9 | 23-24.9 | 25-29.9 | ≥30.0 |
Ideal waist circumference | Male | Female |
Less than 90cm (35.5 inches) | Less than 80cm (31.5 inches) |
Category | Example |
First category Low in calories, eat freely |
|
Second category Contain essential nutrients, eat adequately |
|
Third category High in calories, sugar and fat, eat less |
|
Drug | Function | Target | Side-effects | Usage |
Phentermine | Inhibit appetite | For people whose BMI is over 30.0 kg/m2, or BMI over 27.0 kg/m2 and have comorbidities, this drug can be used together with diet control and exercise to control body weight. | Long-term usage can lead to serious side-effects, such as severe pulmonary vascular disease and heart problems. | Approved for short-term use only (3 months or below) |
Orlistat | Prevent digestion and absorption of fat in our body | For people whose BMI is over 30.0 kg/m2, or BMI over 27.0 kg/m2 and have comorbidities, this drug can be used together with diet control and exercise to control body weight. | Steatorrhea (fat in stools), incontinence | Approved for use to treat obesity |
Liraglutide | Increase our sense of fullness, reduce hunger sign | For people whose BMI is over 30.0 kg/m2, or BMI over 27.0 kg/m2 and have comorbidities, this drug can be used together with diet control and exercise to control body weight. | Mild side-effects such as nausea, diarrhoea, constipation. | Approved for use to treat obesity |
Endoscopic weight loss procedures are not a permanent weight reduction treatment and provide only temporary control of body weight. These procedures are relatively safe compared to surgery but still carry certain risks.